AGC Biologics to Prepare Late-Phase and Commercial Runs for Immunocore

AGC Biologics

Global CDMO’s Heidelberg site to support Process Performance Qualification for IMC-F106C late-stage program and prepare for commercial readiness.

Today, we announced a new late-stage clinical and process performance qualification (PPQ) project at our Heidelberg, Germany site with Immunocore Holdings Plc (Nasdaq: IMCR). Immunocore intends to use the Heidelberg site to complete late-stage manufacturing and prepare for commercialization for IMC-F106C, Immunocore’s PRAME-targeted bispecific therapy.   

Under the agreement, AGC Biologics will leverage our microbial fermentation and manufacturing experience to perform bench-scale qualification and process characterization, and other required studies to support phase III manufacturing, as well as PPQ runs. Pending a successful PPQ campaign and regulatory approvals, the Immunocore project is expected to move into commercial stages at the AGC Biologics Heidelberg site.  

Read full article on

Share this page on social

Ready to get started? See what Samba can do for you.